Abstract:There are many virulence factors of H. pylori that contribute in diverse ways to gastric disease. Therefore, designing multivalent epitope vaccines against many key virulence factors virulence factors of H. pylori is a promising strategy to control H. pylori infection. In previous studies, we constructed a multivalent epitope vaccine FVpE against four key virulence factors of H. pylori (Urease, CagA, VacA, and NAP), and oral immunization with the FVpE vaccine plus a polysaccharide adjuvant (PA) containing lycium barbarum polysaccharide and chitosan could provide protection against H. pylori infection in the Mongolian gerbil model. Oral vaccines have many advantages over injected vaccines, such as improved safety and compliance, and easier manufacturing and administration. However, the harsh gastrointestinal (GI) environment, such as gastric acid and proteolytic enzymes, limits the development of oral vaccines to some extent. Oral vaccines need a gastrointestinal delivery system with high safety, low price and promoting vaccine antigen to stimulate immune response in the gastrointestinal mucosa. Lactic acid bacteria are gastrointestinal probiotics that have unique advantages as a delivery system for oral vaccines. In this study, a M cell-targeting surface display system for L. lactis named plSAM was designed to help vaccine antigens to stimulate effective immune responses in the gastrointestinal tract, and a M cell-targeting recombinant L. lactis vaccine LL-plSAM-FVpE was constructed by using the surface display system plSAM. recombinant L. lactis vaccine LL-plSAM-FVpE could secretively express the SAM-FVpE protein and display it on the bacterial surface. Moreover, experimental results confirmed that LL-plSAM-FVpE had an enhanced M cell-targeting property. In addition, LL-plSAM-FVpE had excellent M cell-targeting property to promote the phagocytosis and transport of the antigen SAM-FVpE by gastrointestinal M cells. More importantly, oral immunization of LL-plSAM-FVpE or SAM-FVpE plus PA can stimulate IgG and sIgA antibodies and CD4 + T cell immune responses against four virulence factors of H. pylori (Urease, CagA, VacA, and NAP), thus providing protective immunity against H. pylori infection in mice. The M cell-targeting recombinant L. lactis vaccine against various key H. pylori virulence factors could be a promising vaccine candidate for controlling H. pylori infection.

Nongenetically Modified Lactococcus Lactis‐adjuvanted Vaccination Enhanced Innate Immunity Against Helicobacter Pylori

Therapeutic efficacy of oral immunization with a non-genetically modified Lactococcus lactis-based vaccine CUE-GEM induces local immunity against Helicobacter pylori infection

Oral Vaccination of Mice Against Helicobacter Pylori with Recombinant Lactococcus Lactis Expressing Urease Subunit B.

Immunoprotection of Recombinant Antigen LTB-UreB-HpaA in Helicobacter Pylori Infected Mice and Immunoenhancement of the Inner Adjuvant LTB

[Immunoprotective Effects of Helicobacter Pylori UreB and HpaA Bivalence Recombinant Vaccine with Inner Adjuvant on Experimental Infection in Mice].

Outer Membrane Vesicles of Helicobacter pylori 7.13 as Adjuvants Promote Protective Efficacy Against Helicobacter pylori Infection

Recombinant outer membrane vesicles delivering eukaryotic expression plasmid of cytokines act as enhanced adjuvants against <i>Helicobacter pylori</i> infection in mice

Oral Immunization with Recombinant Lactococcus Lactis Delivering a Multi-Epitope Antigen CTB-UE Attenuates Helicobacter Pylori Infection in Mice.

Recombinant Outer Membrane Vesicles Coupled with Cytokines Act As High-Performance Adjuvants Againsthelicobacter Pyloriinfection in Mice

Recombinant outer membrane vesicles delivering eukaryotic expression plasmid of cytokines act as enhanced adjuvants against Helicobacter pylori infection in mice

Promoting Immune Efficacy of the Oral Helicobacter Pylori Vaccine by HP55/PBCA Nanoparticles Against the Gastrointestinal Environment

Oral immunization of BALB/c mice with recombinant Helicobacter pylori antigens and double mutant heat-labile toxin (dmLT) induces prophylactic protective immunity against H. pylori infection

Oral Live-Carrier Vaccine of Recombinant Lactococcus lactis Inducing Prophylactic Protective Immunity Against Helicobacter pylori Infection

Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection.

TH Immune Response in Gastric Mucosa by Immunization Using H. Pylori Vaccine with Chitosan As Adjuvant

Antibody Production and Th1-biased Response Induced by an Epitope Vaccine Composed of Cholera Toxin B Unit and Helicobacter pylori Lpp20 Epitopes

Orally-administered outer-membrane vesicles from Helicobacter pylori reduce H. pylori infection via Th2-biased immune responses in mice

Immunogenicity Characterization of the Multi-Epitope Vaccine CTB-UE with Chitosan-Cpg As Combination Adjuvants Against Helicobacter Pylori.

Oral Immunization With a M Cell-Targeting Recombinant L. Lactis Vaccine LL-plSAM-FVpE Stimulate Protective Immunity Against H. Pylori in Mice

Immunologic Properties and Therapeutic Efficacy of a Multivalent Epitope‐based Vaccine Against Four Helicobacter Pylori Adhesins (urease, Lpp20, HpaA, and CagL) in Mongolian Gerbils

Oral multivalent epitope vaccine, based on UreB, HpaA, CAT, and LTB, for prevention and treatment of Helicobacter pylori infection in C57BL / 6 mice